Chimeric Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

ASX:CHM Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
09 Dec 24	BuyAU$800,057	Paul Hopper	Individual		100,000,000	AU$0.008
09 Dec 24	BuyAU$800,057	Paul Hopper	Individual		100,000,000	AU$0.008

Insider Trading Volume

Insider Buying: CHM insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CHM?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	17,500,000	1.76%
Institutions	39,276,136	3.95%
Individual Insiders	287,250,505	28.9%
General Public	651,114,179	65.4%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.1%.

Top Shareholders

Top 15 shareholders own 34.57% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
20.4%	Paul Hopper	203,289,694	AU$1.4m	96.8%	no data
2.18%	The Lind Partners, LLC	21,676,135	AU$151.7k	0%	0.82%
1.77%	Zerrin Investments Pty Ltd, Asset Management Arm	17,600,001	AU$123.2k	0%	12.34%
1.46%	Michael Stewart	14,500,000	AU$101.5k	0%	no data
1.22%	Christine Brown	12,163,170	AU$85.1k	0%	no data
1.21%	Valentino Fazio	12,000,000	AU$84.0k	0%	no data
1.16%	Michael Barish	11,522,634	AU$80.7k	0%	no data
1.04%	Phillip Hains	10,326,028	AU$72.3k	0%	no data
1%	Su-Ming Wong	9,969,684	AU$69.8k	0%	no data
0.9%	Syrax Investments Pty Ltd	9,000,000	AU$63.0k	0%	no data
0.85%	Mbantua Holdings Pty Ltd	8,500,000	AU$59.5k	0%	no data
0.43%	Eliot Bourk	4,230,603	AU$29.6k	0%	no data
0.38%	Jenny Zhang	3,754,781	AU$26.3k	0%	no data
0.38%	Tim Bensley	3,754,781	AU$26.3k	0%	no data
0.17%	Lesley Russell	1,739,130	AU$12.2k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/03 15:02
End of Day Share Price	2025/01/03 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chimeric Therapeutics Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Hunter Diamond	Diamond Equity Research LLC
Maxim Jacobs	Edison Investment Research
null null	Lodge Partners Pty Ltd.